Asia Deal Watch: Ambrx, NovoCodex Partner On Second ADC Candidate, For CD70-Positive Cancers
Executive Summary
Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.
You may also be interested in...
Finance Watch: iTeos, Pandion And Aspen Show COVID-19 Hasn’t Slowed VC Deals Yet
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Strong Early Promise For Takeda 'Off The Shelf' CAR-NK Therapy
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Start-Up Quarterly Statistics: Financings Surged In Q4 While M&A Waned
A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.
Need a specific report? 1000+ reports available
Buy Reports